A change in the timing for starting systemic therapies for hepatocellular carcinoma: the comparison of sorafenib and lenvatinib as the first-line treatment
CONCLUSIONS: The emergence of lenvatinib has encouraged physicians to start systemic chemotherapy earlier in intermediatestage HCC patients.PMID:33639695
Source: Acta Gastro-Enterologica Belgica - Category: Gastroenterology Authors: T Hatanaka S Kakizaki T Nagashima T Ueno M Namikawa H Tojima D Takizawa A Naganuma H Arai K Sato N Harimoto K Shirabe T Uraoka Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | Statistics | Study | Urology & Nephrology